129 related articles for article (PubMed ID: 32667798)
1. Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors.
Robles O; Jackson JJ; Marshall L; Talay O; Chian D; Cutler G; Diokno R; Hu DX; Jacobson S; Karbarz E; Kassner PD; Ketcham JM; McKinnell J; Meleza C; Reilly MK; Riegler E; Shunatona HP; Wadsworth A; Younai A; Brockstedt DG; Wustrow DJ; Zibinsky M
J Med Chem; 2020 Aug; 63(15):8584-8607. PubMed ID: 32667798
[TBL] [Abstract][Full Text] [Related]
2. Tumors establish resistance to immunotherapy by regulating T
Marshall LA; Marubayashi S; Jorapur A; Jacobson S; Zibinsky M; Robles O; Hu DX; Jackson JJ; Pookot D; Sanchez J; Brovarney M; Wadsworth A; Chian D; Wustrow D; Kassner PD; Cutler G; Wong B; Brockstedt DG; Talay O
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243932
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a Potent and Selective CCR4 Antagonist That Inhibits T
Jackson JJ; Ketcham JM; Younai A; Abraham B; Biannic B; Beck HP; Bui MHT; Chian D; Cutler G; Diokno R; Hu DX; Jacobson S; Karbarz E; Kassner PD; Marshall L; McKinnell J; Meleza C; Okal A; Pookot D; Reilly MK; Robles O; Shunatona HP; Talay O; Walker JR; Wadsworth A; Wustrow DJ; Zibinsky M
J Med Chem; 2019 Jul; 62(13):6190-6213. PubMed ID: 31259550
[TBL] [Abstract][Full Text] [Related]
4. A CCR4 antagonist enhances DC activation and homing to the regional lymph node and shows potent vaccine adjuvant activity through the inhibition of regulatory T-cell recruitment.
Yamamoto S; Matsuo K; Nagakubo D; Higashiyama S; Nishiwaki K; Oiso N; Kawada A; Yoshie O; Nakayama T
J Pharmacol Sci; 2018 Mar; 136(3):165-171. PubMed ID: 29519579
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Ohue Y; Nishikawa H
Cancer Sci; 2019 Jul; 110(7):2080-2089. PubMed ID: 31102428
[TBL] [Abstract][Full Text] [Related]
6. CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer.
Maeda S; Murakami K; Inoue A; Yonezawa T; Matsuki N
Cancer Immunol Res; 2019 Jul; 7(7):1175-1187. PubMed ID: 31160277
[TBL] [Abstract][Full Text] [Related]
7. CCR4 Antagonists Inhibit T
Ketcham JM; Marshall LA; Talay O
ACS Med Chem Lett; 2018 Oct; 9(10):953-955. PubMed ID: 30344896
[TBL] [Abstract][Full Text] [Related]
8. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination.
Bayry J; Tchilian EZ; Davies MN; Forbes EK; Draper SJ; Kaveri SV; Hill AV; Kazatchkine MD; Beverley PC; Flower DR; Tough DF
Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10221-6. PubMed ID: 18621704
[TBL] [Abstract][Full Text] [Related]
9. Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma.
Sun W; Li WJ; Wei FQ; Wong TS; Lei WB; Zhu XL; Li J; Wen WP
Oncotarget; 2016 Jun; 7(25):37714-37727. PubMed ID: 27177223
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus-positive pyothorax-associated lymphoma expresses CCL17 and CCL22 chemokines that attract CCR4-expressing regulatory T cells.
Higuchi T; Matsuo K; Hashida Y; Kitahata K; Ujihara T; Taniguchi A; Yoshie O; Nakayama T; Daibata M
Cancer Lett; 2019 Jul; 453():184-192. PubMed ID: 30953706
[TBL] [Abstract][Full Text] [Related]
11. Foxp3
Maeda S; Nakazawa M; Uchida M; Yoshitake R; Nakagawa T; Nishimura R; Miyamoto R; Bonkobara M; Yonezawa T; Momoi Y
Vet Pathol; 2020 Jul; 57(4):497-506. PubMed ID: 32347186
[TBL] [Abstract][Full Text] [Related]
12. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells.
Chang DK; Sui J; Geng S; Muvaffak A; Bai M; Fuhlbrigge RC; Lo A; Yammanuru A; Hubbard L; Sheehan J; Campbell JJ; Zhu Q; Kupper TS; Marasco WA
Mol Cancer Ther; 2012 Nov; 11(11):2451-61. PubMed ID: 22869555
[TBL] [Abstract][Full Text] [Related]
13. Fully human antagonistic antibodies against CCR4 potently inhibit cell signaling and chemotaxis.
Hagemann UB; Gunnarsson L; GĂ©raudie S; Scheffler U; Griep RA; Reiersen H; Duncan AR; Kiprijanov SM
PLoS One; 2014; 9(7):e103776. PubMed ID: 25080123
[TBL] [Abstract][Full Text] [Related]
14. Clinical Application of Anti-CCR4 Monoclonal Antibody.
Ueda R
Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
[TBL] [Abstract][Full Text] [Related]
15. Dosing optimization of CCR4 immunotoxin for improved depletion of CCR4
Wang Z; Louras NJ; Lellouch AG; Pratts SG; Zhang H; Wang H; Huang CA; Cetrulo CL; Madsen JC; Sachs DH; Wang Z
Mol Oncol; 2018 Aug; 12(8):1374-1382. PubMed ID: 29873181
[TBL] [Abstract][Full Text] [Related]
16. Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer.
Maeda S; Motegi T; Iio A; Kaji K; Goto-Koshino Y; Eto S; Ikeda N; Nakagawa T; Nishimura R; Yonezawa T; Momoi Y
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131860
[TBL] [Abstract][Full Text] [Related]
17. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens.
Pere H; Montier Y; Bayry J; Quintin-Colonna F; Merillon N; Dransart E; Badoual C; Gey A; Ravel P; Marcheteau E; Batteux F; Sandoval F; Adotevi O; Chiu C; Garcia S; Tanchot C; Lone YC; Ferreira LC; Nelson BH; Hanahan D; Fridman WH; Johannes L; Tartour E
Blood; 2011 Nov; 118(18):4853-62. PubMed ID: 21908423
[TBL] [Abstract][Full Text] [Related]
18. Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients.
Kurose K; Ohue Y; Wada H; Iida S; Ishida T; Kojima T; Doi T; Suzuki S; Isobe M; Funakoshi T; Kakimi K; Nishikawa H; Udono H; Oka M; Ueda R; Nakayama E
Clin Cancer Res; 2015 Oct; 21(19):4327-36. PubMed ID: 26429981
[TBL] [Abstract][Full Text] [Related]
19. [Anti-CCR4 mAb and regulatory T cells].
Kurose K; Ohue Y; Oka M
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1150-5. PubMed ID: 24047773
[TBL] [Abstract][Full Text] [Related]
20. Treg depletion in non-human primates using a novel diphtheria toxin-based anti-human CCR4 immunotoxin.
Wang Z; Pratts SG; Zhang H; Spencer PJ; Yu R; Tonsho M; Shah JA; Tanabe T; Powell HR; Huang CA; Madsen JC; Sachs DH; Wang Z
Mol Oncol; 2016 Apr; 10(4):553-65. PubMed ID: 26643572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]